VARIABILITY IN NOAC DOSE ELIGIBILITY AND ADJUSTMENT ACCORDING TO RENAL FORMULAE AND CLINICAL OUTCOMES IN AF PATIENTS WITH AND WITHOUT CKD: INSIGHTS FROM ORBIT AF II

Abstract

Non-Vitamin K Oral Anticoagulants (NOACs) are used for prevention of thromboembolism in patients with atrial fibrillation (AF). Guidelines recommend dose adjustment based on kidney function.The most common estimates of kidney function employed in clinical practice are derived from glomerular filtration rate (eGFR), however, product monographs recommend the use of the Cockcroft-Gault creatinine clearance equation (eCrCl) for dose adjustment. We sought to evaluate misclassification of NOAC renal dosing using eGFR versus eCrCl.